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Abstract
Previous studies on the effect of repeated electro-acupuncture (EA) treatments in rats with
steriod-induced polycystic ovaries (PCO), EA has been shown to modulate nerve growth factor
(NGF) concentration in the ovaries as well as corticotropin releasing factor (CRF) in the median
eminence (ME). In the present study we tested the hypothesis that repeated EA treatments
modulates sympathetic nerve activity in rats with PCO. This was done by analysing endothelin-1
(ET-1), a potent vasoconstrictor involved in ovarian functions, as well as NGF and NGF mRNA
expression involved in the pathophysiological process underlying steroid-induced PCO.
The main result in the present study was that concentrations of ET-1 in the ovaries were
significantly lower in the PCO group receiving EA compared with the healthy control group (p <
0.05). In the hypothalamus, however, ET-1 concentrations were found to be significantly higher in
the PCO group receiving EA than in the healthy control group (p < 0.05). Concentrations of
ovarian NGF protein were significantly higher in the PCO control group compared with the healthy
control group (p < 0.001), and these concentrations decreased significantly after repeated EA
treatments compared with those in the PCO control group (p < 0.05) and were found to be the
same as those in the healthy control group. In conclusion, these results indicate that EA modulates
the neuroendocrinological state of the ovaries, most likely by modulating the sympathetic nerve
activity in the ovaries, which may be a factor in the maintenance of steroid-induced PCO.
Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy in women of reproductive ages [1]. The
aetiology of PCOS is unclear, but there are indications
that the syndrome is associated with increased sympathet-
ic nerve activity [2–4]. A single intramuscular injection of
Published: 8 April 2003
Reproductive Biology and Endocrinology 2003, 1:33
Received: 28 March 2003
Accepted: 8 April 2003
This article is available from: http://www.RBEj.com/content/1/1/33
© 2003 Stener-Victorin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted 
in all media for any purpose, provided this notice is preserved along with the article's original URL.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/33
Page 2 of 8
(page number not for citation purposes)
estradiol valerate (EV) in cycling rats results in loss of oe-
strus cyclicity, anovulation, and the formation of follicu-
lar cysts [4–6]. These changes exhibited by the steroid-
induced polycystic ovary (PCO) share many of the endo-
crinological and morphological abnormalities seen in hu-
man PCOS, and an association with increased
sympathetic nerve activity has been suggested [4,7]. We
recently showed that a treatment known to influence the
activity of the sympathetic nervous system – repeated
treatments of electro-acupuncture (EA) – improved hor-
monal and metabolic profiles and induced ovulation in
women with PCOS and anovulation [8]. Even if human
PCOS cannot be reproduced exactly in a rat model, the
steroid-induced PCO model may be a great help in study-
ing the physiological mechanisms of reported effects of
EA.
Endothelin-1 (ET-1) is a 21-amino acid peptide, consid-
ered to be a potent and long-lasting vasoconstrictor [9].
ET-1 exerts a wide spectrum of biological activities in ad-
dition to vasoconstriction and is reported to be involved
in ovarian functions in the human [10]. A recent study
found that women with PCOS had elevated concentra-
tions of plasma ET-1 compared with a healthy control
group [11]. This finding supports the theories of a link be-
tween ET-1 and increased sympathetic nerve activity asso-
ciated with PCOS in women. Nerve growth factor (NGF)
is synthesized by and released from ovarian cells and the
presence of NGF receptors on nerve fibres innervating the
ovary suggests that NGF is one of the target-derived neu-
rotrophins involved in the development and maintenance
of ovarian innervation [12]. Recent data indicate that ab-
normally elevated concentrations of ovarian NGF after a
single dose of EV may contribute to ovarian dysfunction
since an activation of ovarian NGF synthesis precedes the
formation of follicular cysts [4]. This increased synthesis
was correlated with exaggerated steroid secretory activity
in the ovaries [7]. Recently we found that repeated EA
treatments in the steroid-induced rat PCO model used in
this study significantly reduced increased concentrations
of ovarian NGF and of median eminence (ME) corticotro-
pin-releasing factor (CRF) [13,14], which indicates a func-
tional interaction between activity in the nervous and
endocrine systems.
In the present study we tested the hypothesis that repeated
EA treatments modulates sympathetic nerve activity in
rats with steroid-induced PCO. This was done by analys-
ing ET-1 concentrations in the CNS and in endocrine tar-
get organs such as the adrenal gland and the ovary. In
addition, the concentration of NGF protein and the ex-
pression of NGF mRNA in the ovary, the adrenal gland,
and the spinal cord were analysed. Morphological analy-
ses of the ovaries were made to confirm the induction of
PCO in the rat model used in this study.
Materials and methods
Fifty-six virgin adult cycling Sprague-Dawley rats (Mölle-
gaard, Denmark) weighing 195–210 g, with regular 4-day
oestrus cycles were divided into three groups. They were
housed four to each cage at a controlled temperature of
22°C with a 12-h light/12-h dark cycle for at least 1 week
before and throughout the experimental periods. The rats
had free access to pelleted food and tap water. Thirty-two
rats, those in the PCO groups described below, were each
given a single i.m. injection of 4 mg EV (Riedeldehaen,
Germany) in 0.2 ml oil to induce well-defined PCO.
Twenty-four rats, those in the healthy control groups de-
scribed below, received a single i.m. injection of 0.2 ml oil
only. The studies were approved by the local Ethics Com-
mittee for Animals at Göteborg University.
EA Treatment
In Part I of the experiment, the rats were divided into three
experimental groups: i) a healthy control group (vehicle
control), (n = 8) ii) a PCO control group (n = 8), and iii) a
PCO group receiving EA (n = 8). In Part II of the experi-
ment, the rats were divided into four experimental groups:
i) a healthy control group (vehicle control) (n = 8), ii) a
healthy control group receiving EA (vehicle – EA) (n = 8), iii)
a PCO control group (n = 8), and iiii) a PCO group receiving
EA (n = 8).
All groups were anaesthetised as described below for 25
minutes, 12 times, corresponding to the EA treatment giv-
en to the groups receiving EA. EA was given during anaes-
thesia every second or third day beginning 2 days after the
EV injection. The points chosen for stimulation were bilat-
eral in the mm. biceps femoris and erector spinae, in so-
matic segments corresponding to the innervation of the
ovaries. The needles (Hegu: Hegu AB, Landsbro, Sweden)
were inserted to depths of 0.5–0.8 cm and then attached
bilaterally to an electrical stimulator (CEFAR ACU II, Ce-
far, Lund, Sweden). The points were electrically stimulat-
ed with a low burst frequency of 2 Hz; each pulse has a
duration of 180 µsec, a burst length of 0.1 sec and a burst
frequency of 80 Hz. The intensity was adjusted until local
muscle contractions were seen (1.5 mA) to reflect the ac-
tivation of muscle-nerve afferents (A-delta fibres and pos-
sibly C fibres). The location and type of stimulation were
the same in all rats.
Anaesthetization
In Part I, designed to measure ET-1 concentrations, all rats
were anaesthetized superficially with enfluran (EFRANE®,
Abbott Scandinavia, Kista, Sweden). On day 30 after i.m.
injection of EV, the rats were decapitated, i.e. 1–2 days af-
ter the last EA treatment. In Part II, designed to measure
concentrations of NGF protein and expression of NGF
mRNA, all rats were anaesthetized superficially with an
i.p. injection of a mixture of Ketamin (50 mg/kg; PARKE-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/33
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DAVIS, Warner Lambert Nordic AB, Solna, Sweden) and
Rompun (20 mg/kg; Bayer, Bayer AG, Leverkusen, Germa-
ny) and by inhalation of Isofluran (Baxter Medical AB,
Kista, Sweden). On day 30 after i.m. injection of EV, the
rats were decapitated, i.e. 1–2 days after the last EA
treatment.
Radioimmunoassay of ET-1
After the rats in Part I, designed to allow measurement of
ET-1, were decapitated on day 30, the ovaries, the adrenal
glands, and the hypothalamus were quickly removed and
dissected on dry ice, weighed, and stored at -80°C until
extraction. During extraction, the frozen tissues were
weighed, cut into small pieces, then boiled for 10 minutes
in 10 volumes of 1 mol/l acetic acid. After homogeniza-
tion with a steel rod and a vortex mixer, the samples were
centrifuged at 3000 × g for 15 minutes. The supernatants
were lyophilized, then diluted in 10 ml of radioimmu-
noassay (RIA) buffer and kept at -20°C until analysis.
ET-1 was analysed using a non-equilibrium competitive
immunoassay. The RIA was based on antiserum END 4,
which had been collected from a rabbit that had been im-
munized with ET-1 and been coupled to bovine serum al-
bumin (BSA) using the carbodimide method. ET-1 was
labelled to a specific activity of 59 Bq/fmol using the chlo-
ramine-T method and subsequently purified by reverse-
phase HPLC. Briefly, the assay was carried out by incubat-
ing the calibrators and samples with the antiserum in a fi-
nal dilution of 1:7 500 for 48 h at 4°C. 125I-labelled ET-1
was then added to the samples, which were incubated for
a further 24 h at 4°C. Separation was performed using a
donkey anti-rabbit antibody-coated cellulose suspension
(Sac-cel; Labkemi, Stockholm, Sweden). Synthetic ET-1
(Peninsula laboratories, Belmont, California, USA) served
as a calibrator. The buffer blank counts were subtracted
from all counts before the standard curve was evaluated
(RiaCalc; Wallac, Redmond, Washington, USA) and con-
centrations were determined. The sample blanks did not
differ statistically from the buffer blank. The amount of
ET-1 required to reduce the binding of the radioligand by
50% (IC50) was 7.4 pmol/l. The intra- and interassay co-
efficients of variation were 5% and 8% respectively at 25
pmol/l. When the cross-reactivity of antiserum END 4 to
ET-1 was used as a 100% reference, the cross-reactivities
were as follows: ET-2, 32%; ET-3, 120%; big ET, 6%. For
methodological details see Lemne et al. (1994) [15].
Enzyme Immunoassay of NGF protein and RT-PCR-ELISA 
of mRNA NGF
After the rats in Part II, designed to allow measurement of
NGF protein and mRNA NGF, were decapitated on day
30, the ovaries, the adrenal glands, and the dorsal part of
the spinal cord were quickly removed and dissected on
dry ice, weighed, and stored at -80°C until extraction.
ELISA
The samples were sonicated in extraction buffer (0.1% Tri-
ton X-100, 100 mM Tris-HCl, pH 7.2, 400 mM NaCl, 4
mM EDTA, 0.2 mM PMSF, 0.2 mM benzethonium chlo-
ride, 2 mM benzamidine, 40 U/ml aprotinin, 0.05% sodi-
um azide, 2% BSA, and 0.5% gelatine; 1 ml/100 mg of
tissue) followed by centrifugation at 10 000 × g for 30
minutes. The supernatants were used for the assay. The bi-
oactive form of 2.5S NGF, purified from mouse submaxil-
lary glands and prepared in the laboratory at the Institute
of Neurobiology (CNR) in Rome, Italy, according to the
method of Bocchini and Angeletti (1969) [16], was used
as a standard. NGF was dissolved in extraction buffer and
the standard curve was in a range of 1000 pg ml (-1) and
15.6 pg ml (-1). Enzyme-linked immunosorbent assays
(ELISA) were performed as described by Wescamp and
Otten (1987) [17] with a minor modification [18]. Specif-
ic NGF binding was assessed by use of monoclonal mouse
anti β-2.5S NGF (Boehringer Mannheim), which reacts
with both the 2.5S and the 7S biologically active forms of
NGF. All assays were performed in triplicate, and the ab-
sorbency of the samples and standards was corrected for
non-specific binding (i.e. the absorbency in a well coated
with purified mouse IgG). The content of NGF in the sam-
ples was determined in relation to the NGF standard
curve. Data were not corrected for recovery of NGF from
samples, which was routinely above 90%. With these cri-
teria, the limit of sensitivity of NGF ELISA averaged 0.5 pg
per assay.
RT-PCR-ELISA
The concentrations of NGF mRNA were evaluated using
the reverse transcriptase-polymerase chain reaction (RT-
PCR) ELISA protocol, exactly as previously described by
Tirassa and co-workers (2000) [19]. The total RNA was ex-
tracted from the ovaries, adrenal glands, and spinal cord
by using the method of [20] as modified in the TRIzol Kit
(Invitrogen AB, Lidingö, Sweden). Complementary DNA
was synthesized from 1 µg of total RNA using 200 Units
of M-MLV reverse transcriptase (Promega Italia, Milan, It-
aly) in 20 µl of total volume reaction. NGF. Glyceralde-
hyde-3-phosphate dehydrogenas (GAPDH) genes were
co-amplified in a single-tube PCR reaction (30 cycles: 1
minute at 95°C; 1 minute at 55°C; 2 minutes at 72°C) us-
ing 5'-biotinylated specific primers to generate biotinylat-
ed PCR products detectable by digoxygenin labeled
probes in an immuno-enzymatic assay. The amount of
amplified products was measured at an optical density
(O.D.) of 450/690 nm (O.D. 450/690) using a Dynatech
ELISA Reader 5000. A GAPDH level of O.D. 450/690 was
used to normalise the relative differences in sample size,
differences in integrity of the individual RNA, and varia-
tions in reverse transcription efficiency. For exact method-
ological details and the primer/probe sequences, see
Tirassa et al. [19].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/33
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Ovarian morphology
After the rats in Part II were decapitated on day 30, one
ovary per rat was removed, cleaned of adherent connec-
tive fat tissue, and fixed in 4% formaldehyde buffer for at
least 24 hours. Thereafter the samples were dehydrated
and imbedded in paraffin. The ovaries were longitudinal-
ly sectioned, with a thickness of 4 µ, and every tenth sec-
tion – six section from each ovary were taken and stained
with haematoxylin-eosin. An experienced pathologist
(SC), blinded to grouping analysed the follicle population
under microscope. There was no intention to quantify the
number of growing or atretic follicles but rather to estab-
lish whether ovulation with corpora lutea formation had
occurred within the given time frame. According to mor-
phometric (stereological) and statistical principles there
are no need to perform a statistical analysis in this
situation.
Statistical analyses
All data were analysed using the software package SPSS
10.0. ET-1 concentrations in the ovaries, the adrenal
glands, and the hypothalamus were evaluated using the
analysis of variance (ANOVA), and the groups were tested
using multiple comparisons with the correction of Bonfer-
roni. All results are reported as a mean ± standard error of
mean (SEM). A p-value less than 0.05 was considered
significant.
Results
ET-1 changes after EV injection and response to electro-
acupuncture
Means ± SEM for ET-1 concentrations (pmol/g) in the
ovaries, the adrenal glands, and the hypothalamus in all
groups are presented in Table 1. These analyses were per-
formed to determine whether ET-1 concentrations are af-
fected in the steroid-induced rat PCO model and if
repeated EA treatments modulate ET-1 concentrations.
Ovarian ET-1 concentrations were significantly lower in
the PCO group receiving EA than in the healthy control
group (p < 0.05). The ET-1 concentrations in the hypoth-
alamus were significantly higher in the PCO group receiv-
ing EA than in the healthy control group (p < 0.05). The
ET-1 concentrations in the adrenal glands were not signif-
icantly different between the groups.
NGF changes after EV injection and response to electro-
acupuncture
Means ± SEM for NGF protein (pg/g) concentrations and
NGF mRNA (O.D. 450/690) in the ovaries, the adrenal
glands and the spinal cord in Table 2. These analyses were
performed to determine whether NGF production is in-
creased as previously reported [4] and, if so, whether re-
peated EA treatment modulates this increase [13].
Concentrations of ovarian NGF protein were significantly
higher in the PCO control group than in either the healthy
control group (p < 0.001) or the healthy group receiving EA (p
< 0.001). Repeated EA treatments resulted in significantly
lower concentrations of ovarian NGF protein in the PCO
group receiving EA than in the PCO control group (p < 0.05).
The ovarian concentrations of NGF protein in the healthy
control group, the healthy group receiving EA, and the PCO
group receiving EA, however, were similar. No significant
differences in NGF concentrations in the adrenal glands or
the spinal cord were found. The expressions of ovarian
NGF mRNA was significantly depressed in the PCO control
group compared with both the healthy control group (p <
0.05) and the healthy group receiving EA (p < 0.05). The
PCO group receiving EA, however, differed from neither the
healthy control group nor the healthy group receiving EA.
Ovarian morphology – day 30
The ovaries in the healthy control group and in the
healthy group receiving EA exhibited a typically normal
appearance with follicles and corpora lutea in different
stages of development and regression. The ovaries in both
the PCO control group and in the PCO group receiving EA
displayed typical PCO-like changes [4], and both the
number and size of the corpora lutea in these groups were
decreased compared with in the healthy groups. Typically,
no young corpora lutea were present in the two PCO
groups. The dominant structures were atretic follicles, re-
gressing old corpora lutea, and a few growing "healthy"
Table 1: Endothelin-1 (ET-1) concentrations (mean ± SEM) in the ovaries, the adrenal glands, and the hypothalami in the three 
experimental groups the healthy control group, the polycystic ovary (PCO) control group, and the PCO group receiving electro-acupuncture 
(EA).
ET-1 concentrations (pmol/g)
Healthy control PCO Control PCO EA
Ovary 0.44 ± 0.11 0.38 ± 0.14 0.15 ± 0.05a
Adrenal gland 0.01 ± 0.01 0.05 ± 0.02 0.06 ± 0.04
Hypothalamus 0.14 ± 0.05 0.33 ± 0.10 0.71 ± 0.23a
a p < 0.05 when the PCO group receiving EA were compared with the healthy controls.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/33
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follicles in the primary, secondary, and tertiary stages (Fig-
ures 1 and 2).
No substantial morphological differences were found be-
tween the groups treated with EA (healthy and PCO) and
the control groups (healthy and PCO).
Discussion
The main result in the present study was that repeated
treatments with low-frequency (2-Hz) EA significantly de-
creased ovarian concentrations of ET-1 and NGF protein
in rats with steroid-induced PCO. This is an indication of
lower activity in the sympathetic nerve fibres of the ova-
ries and is in agreement with our previous results of NGF
and CRF measurements in the same rat PCO model
[13,14]. In addition, the ovarian morphology confirms
the validity of the present rat PCO model.
ET-1 as well as NGF has previously been shown to act di-
rectly on ovarian steroidogenesis in cows [21] and rats [7].
In addition, ET-1 concentrations in women with PCOS
were found to be elevated and positively correlated with
peripheral testosterone concentrations [11]. The same
study, incidentally, found that long-term treatment of
these women with the insulin sensitizer metformin  re-
duced concentrations of both plasma androgen and ET-1
and improved insulin sensitivity [11]. This indicates a
possible link between ET-1 and hyperinsulinaemia in
Figure 1
PCO group control group 30 days after EV injection. A. Survey view showing atretic follicles (1), regressing old corpora lutea 
(2), and growing "healthy" follicles (3), ×4 obj. B. Detailed view of an atretic follicle with mainly degenerated granulosa cells and 
macrophages, ×60 obj. C. Part of early atresia in a secondary follicle (right) and interstitial cells (right), ×60 obj. D. Part of a 
growing secondary "healthy" follicle (right) and interstitial cells (left), ×60 obj.
PCO control
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women with PCOS. However, whether there is a connec-
tion between insulin secretion and PCO in the present rat
model was not investigated in the present study. Further-
more, ET-1 has been found to be present in the central
nervous system (CNS) of the rat, probably as a modulator
of the actions of various neuropeptides [22]. ET-1 has
emerged as an important modulator of stress responses in
the CNS [23], as evidenced by the close relationship be-
tween ET-1 and catecholamines in stress provocations.
This relationship most likely varies from region to region
in the CNS. For instance, the effect that ET-1 has on sym-
pathetic nerve activity depends on where in the CNS that
ET-1 was administered [23]. In the present study, ET-1 was
significantly higher in the hypothalamus following the
period of EA treatments. Our findings that hypothalamic
ET-1 concentrations increased while ME CRF concentra-
tions decreased in response to repeated EA treatments sug-
gest that there is a differential response to EA treatment.
It can be speculated that a high content of hypothalamic
ET-1 may reflect two different states, i.e. either a high turn-
over and a high synthesis or a reduced release and, conse-
quently an increase in concentration. CRF is another well-
known modulator of stress responses and has previously
been found to be elevated in the ME of rats with PCO [14].
This supports the theory that sympathetic nerve activity in
the present rat PCO model was disturbed.
It has previously been shown that rats with steroid-in-
duced PCO develop ovarian follicular cysts and that this
development of cysts is preceded by an increased synthe-
sis of NGF in the ovary [4]. These findings suggest that hy-
peractivation of ovarian sympathetic input caused by a
single injection of EV is related to an overproduction of
NGF and enhanced activity in the neurotrophic-neuro-
genic regulatory system and contributes to the process by
which EV induces ovarian cysts and disrupts ovulation in
rats [4]. That the abnormally high sympathetic activity
contributes to the anovulatory state in rats with steroid-in-
duced PCO is supported by the re-establishment of cyclic-
ity and ovulatory capacity in rats that undergo transection
of the superior ovarian nerve or are subjected to ovary-
specific blockade of NGF [4,24].
In the present study, we can confirm that the steroid-in-
duced rat PCO model is associated with increased
concentrations of NGF protein and displays typical PCO-
like changes in the ovarian morphology with a domi-
nance of atretic follicles and decreased numbers and sizes
of corpora lutea. In addition, we were also able to confirm
our previous findings that repeated EA treatments modu-
late the sympathetic output in the ovaries, as evidenced by
the significant decrease in concentrations of ovarian NGF
protein in rats with steroid-induced PCO. Repeated EA
treatment did not, however, reverse the morphological
changes in the rat PCO group. This is in line with our pre-
vious results [4]. The most plausible explanation for the
absence of morphological changes, might be that the EA
stimulation needs to be stronger to alter the ovarian
morphology.
Preliminary data from an ongoing study, investigating the
most optimal intensity and frequency of EA stimulation
on sympathetic outflow show that low frequency is the
most optimal frequency and that the stimulation needs to
be strong (3 mA). The intensity used in this study was 1.5
mA.
Table 2: Nerve Growth Factor (NGF) protein concentrations and NGF mRNA expression (mean ± SEM) in the ovaries, the adrenal 
glands and the dorsal part of the spinal cord in the four experimental groups the healthy control group, the healthy group receiving electro-
acupuncture (EA), the polycystic ovary (PCO) control group, and the PCO group receiving EA.
NGF concentrations (pg/g)
Healthy control Healthy EA PCO control PCO EA
Ovary 294.85 ± 17.00 265.79 ± 20.99 479.77 ± 26.86a 385.34 ± 12.26b
Adrenal gland 102.42 ± 26.14 119.97 ± 51.81 98.82 ± 12.46 94.42 ± 14.32
Spinal cord 867.36 ± 65.52 1600.59 ± 360.03 1351.26 ± 220.82 1081.94 ± 193.72
NGF mRNA expression (O.D. 450/690)
Ovary 1.02 ± 0.19 1.10 ± 0.2 0.35 ± 0.06c 0.45 ± 0.15
Adrenal gland 0.41 ± 0.06 0.51 ± 0.07 0.32 ± 0.06 0.37 ± 0.05
Spinal cord 0.71 ± 0.09 1.15 ± 0.34 0.57 ± 0.08 1.12 ± 0.29
a p < 0.001 when the PCO control group were compared with the healthy control group and healthy group receiving EA. b p < 0.05 when the PCO group 
receiving EA were compared with the PCO control group. c p < 0.001 when the PCO control group were compared with the healthy control group and the 
healthy group receiving EA.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/33
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Surprisingly, the expression of NGF mRNA in the ovaries
was significantly lower in the PCO control group than in the
other three groups: the healthy control group, the healthy
group receiving EA, and the PCO group receiving EA. That
mRNA expression in the PCO group receiving EA did not
differ from that in the healthy control group or the healthy
group receiving EA is contradictory to previous findings in
the same rat PCO model [4]. The most plausible explana-
tion for this discrepancy is that the excessive concentra-
tions of ovarian NGF protein might inhibit the expression
of NGF mRNA in the ovaries. Another possible explana-
tion is that there might be an unbalanced turnover
between NGFmRNA and NGF protein, thus the NGFmR-
NA that is engaged in NGF protein translation is not re-
placed completely, or that in response to EA more NGF is
produced than the quantity required. These findings need
to be further investigated.
The results of ET-1 concentrations in the adrenal glands
and NGF in the spinal cord and in the adrenal glands in-
dicate a close interaction between these two systems, most
likely due to the fact that the adrenal glands are part of the
sympathetic nervous system.
In conclusion, repeated EA treatments significantly de-
crease ovarian concentrations of ET-1 and NGF protein.
This supports our previous finding that EA modulates
sympathetic nerve activity in the ovaries, which may be a
Figure 2
PCO group receiving EA 30 days after EV injection. A. Survey view showing atretic follicles (1), a growing "healthy tertiary fol-
licle (2), and interstitial cells (3), ×10 obj. B. Detailed view with an early atretic follicle in the upper part of the picture and a late 
atretic follicle near the bottom, ×60 obj. C. Part of the growing follicle with many mitotic figures among the granulosa cells, 
×60 obj. D. Detailed view with parts of an interstitial gland and small healthy follicles, ×40 obj.
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factor in the maintenance of steroid-induced PCO. How-
ever, it remains to be elucidated whether these effects of
repeated EA treatments are a result of a direct action on
the ovary, a decrease in the sympathetic outflow to the
ovary, or both.
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